More Argent Biopharma Ltd news
Argent Biopharma LtdASX: RGT

Trial on the Effect of CannEpil on Driver Competency

Aug 23, 2019 at 12:10 AM EDT · Issued by Argent Biopharma Ltd

Filed with ASX · Aug 23, 2019 at 12:10 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/trial-on-the-effect-of-cannepil-on-driver-competency

Argent Biopharma Ltd on 6ix

Story so far

  • Arrival of First CannEpil Shipment to United KingdomMay 7, 2019
  • New Distribution Agreements Signed for CannEpil & IMPsMay 2, 2019
  • Received CannEpil Purchase Orders and Import Permit for UKApr 12, 2019

Earlier from Argent Biopharma

  • Canaccord to Lead LSE Listing and $4.75m Placement ClosedAug 21, 2019
  • MXC 100 Patient Milestone in Aus, Onboards Tetra HealthAug 12, 2019
  • MGC Signs Agreement for Construction of GMP Pharma FacilityAug 8, 2019
  • Additional Information on Ground-breaking ResearchJul 29, 2019
  • MGC Research- Effectiveness of Cannabinoids on Brain CancersJul 23, 2019

Later from Argent Biopharma

  • Approval Granted for Large-Scale Research Project with IHPSAug 26, 2019
  • Appendix 4E and Audited 2019 Financial ReportAug 28, 2019
  • Placement Settlement Complete, Info on the Priority OfferAug 29, 2019
  • Epilepsy Clinical Study Comparing CannEpil to 100% CBDSep 2, 2019
  • 200 Prescription Milestone Passed in Australia & UKSep 17, 2019
All Argent Biopharma news releases↗

Follow Argent Biopharma into a list and get an email when it puts out news.

Follow Argent Biopharma
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer